81 results about "Bowel dysfunction" patented technology

An implantable stimulator(s), small enough to be located near or adjacent to an autonomic nerve(s) innervating urinary and/or gastrointestinal structures, uses a power source/storage device, such as a rechargeable battery. Periodic recharging of such a power source/storage device is accomplished, for example, by inductive coupling with an external appliance. The small stimulator provides a means of stimulating a nerve(s) or other tissue when desired, without the need for external appliances during the stimulation session. When necessary, external appliances are used for the transmission of data to and/or from the stimulator(s) and for the transmission of power, if necessary. In a preferred embodiment, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one implant includes at least one sensor, and the sensed condition is used to adjust stimulation parameters.

Methods and compositions for treating post-surgical gastrointestinal dysfunction are provided. Methods include administering a quaternary derivative of noroxymorphone (e.g., methylnaltrexone) to a patient after a segmental colectomy is performed on the patient.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.

The present disclosure describes novel carbon-based diazeniumdiolates agents and compounds or salts or prodrugs thereof that release nitric oxide for the treatment of neuropathic gastrointestinal dysfunction. The neuropathic gastrointestinal dysfunction refers to disorders associated with motility, sensation and neuromuscular function that include but are not limited to conditions such as delayed gastric emptying.

The invention discloses an enteral nutrition preparation, and a preparation method and applications thereof. The enteral nutrition preparation according to the invention contains the following ingredients by mass percent: 3-20% of marine life protein peptide powder, 1-3% of seawater spirulina powder, 3-5% of fruit and vegetable powder, 3-15% of soybean peptide powder, 2-3% of corn oil, 1-2% of fish oil and 55-75% of maltodextrin. The enteral nutrition preparation according to the invention has good dissolubility as homogeneous solid powder and is homogeneous suspension after being dissolved, and the enteral nutrition preparation also has complete nutrients, easy for digestion, high in content of minerals and vitamins and rich in unsaturated fatty acids such as EPA and DHA, etc., can be used as nutritive support for patients suffering from gastrointestinal dysfunction, is significant to the recovery of body and gastrointestinal functions of the patients suffering from gastrointestinal dysfunction, and can also promote digestion and prominently enhance immunity. The enteral nutrition preparation according to the invention has the advantages of low production cost and being capable of saving energy and enhancing the utilization rate of raw material obviously.

The invention relates to a traditional Chinese medicine composition with functions of improving bowel dysfunction and applications thereof, especially relates to a traditional Chinese medicine composition with functions of improving bowel dysfunction with emotional inducements or accompanied with emotional abnormality and applications thereof, and solves the problem that safety and effective medicines for bowel dysfunction caused by emotion attack or exacerbation or accompanied with emotional abnormality are lacking in the prior art. The traditional Chinese medicine composition is prepared from fried atractylodes, fried white peony roots, albizia flowers, stewed root of kudzu vine, fingered citron, parched hawthorn fruit, Chinese yam and Chinese magnoliavine. The traditional Chinese medicine composition has functions of invigorating spleen, nourishing liver, relieving pain, dispelling melancholy and calming nerve, and can treat diseases of bowel dysfunction induced or aggravated by metal factors, especially abdominal pain and diarrhea accompanied with emotional melancholy, restlessness, anxiety and poor sleep. The traditional Chinese medicine composition has mild medicine properties, can adjust liver and spleen, promote bowel motility and adjust emotions. The traditional Chinese medicine composition can be applied in the traditional Chinese medicine field.

The invention discloses a method for constructing a mouse animal model with a qi-deficiency typegastrointestinal dysfunction. The method comprises the following steps: lavaging a mouse with a supersaturatedmirabilitewater solution for 10-15 days, then lavaging with a sijunzi decoction for 7-10 days, and successfully constructing the mouse animal model with the qi-deficiency typegastrointestinal dysfunction when the mouse has the symptoms in (1), (4) and (6) or more as follows: (1) the weight is reduced, and the fur of the mouse becomes grey, is free of color and luster; (2) the food-intake is reduced; (3) excrement becomes thin; (4) intestinal mucosal injury score becomes poor; (5) the volume of the stomach is increased; and (6) the gastrointestinal carbon powder propulsion index declines. The invention provides the mouse animal model with the qi-deficiency typegastrointestinal dysfunction, which is good in stability, easy to popularize, good in repeatability, economic and practical; and an experimentfoundation is provided for clinical earlier research on treatment of the gastrointestinal dysfunction with traditional Chinese medicines.

The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.

Solid dispersions of stable, amorphous opioid antagonists, particularly [[2(S)-[[4(R)- (3 -hydroxyphenyl)-3(R),4-dimethyl-piperidinyl]methyl] - 1 -oxo-3 -phenylpropyl] amino] acetic acid, with improved water solubility and bioavailability are disclosed. Also disclosed are methods of preventing or treating a side effect associated with an opioid. In addition, methods of treating or preventing pain, ileus, and opioid bowel dysfunction are disclosed.

The invention relates to a dietary fiber product with the function of loosening bowel to relieve constipation and a preparation method thereof. The dietary fiber product is prepared from the followingraw materials in parts by weight: 19-27 parts of rice starch, 25-38 parts of dietary fiber powder, 10-25 parts of vegetable fat powder, 12-19 parts of meringue powder, 1-7 parts of vitamins and minerals, and 1-3 parts of stabilizer; the dietary fiber product prepared by the method is applicable to people with metabolic disorders caused by constipation or bowel dysfunction; a plurality of dietaryfiber powders are mixed in nutrition-allocated proportion to ensure the sufficient contents of soluble dietary fiber and insoluble dietary fiber, so as to scientifically regulate the intestinal floraof patients, improve intestinal functions, realize the effect of loosening the bowel to relieve constipation, maintain intestinal health and improve immunity of the organism.

The invention discloses a pharmaceutical composition for treating bowel dysfunction after an abdominal surgery in order to solve the treatment problem of the bowel dysfunction after the abdominal surgery. The navel-applied agent is characterized by comprising raw materials including, by weight, aspongopus chinensis dallas, alyxia, timonius arboreus, jasminum grandiflorum, caryopteris terniflora maxim, allium victorialis, gastrodia elata bl, spatholobus suberectus dunn, securinega suffruticosa, azurite, cinnamomum cassia presl and setaria italica beauv. Clinical trials prove that the pharmaceutical composition has the advantages of good curative effect on bowel dysfunction, high security, and being worthy of clinical application and promotion.

Provided herein are methods for treating underactive bladder, urinary retention, detrusor-sphincter dyssynergia after spinal cord injury, constipation, and/or infrequent bowel movements including the step of applying electrical stimulation to one or more peripheral nerves.

The invention provides folium mori pea-flour cakes. According to the formula, the folium mori pea-flour cakes comprise the following components in parts by mass: 100 parts of unshelled peas, 45-55 parts of white granulated sugar, 7.0-10 parts of folium mori powder, 6.0-9.0 parts of agar and 0.5-0.8 part of sodium hydrogen carbonate. A preparation method comprises the processes of boiling, blending, molding, cutting, packaging and sterilizing. The folium mori pea-flour cake provided by the invention is unique in formula, excellent in mouth feel and abundant in nutrition, has an obvious health-care function, is suitable for various crowds except for diabetes mellitus patients and obesity patients and is particularly suitable for people with bowel dysfunctions including constipation, unbalanced intestinal microflora, damp and heat of intestinal tracts and the like to eat.

The invention belongs to the technical field of medicine and particularly relates to traditional Chinese medicine composition for treating acute and chronic enteritis, colitis and bowel dysfunction. The traditional Chinese medicine composition is prepared from the following active ingredients in parts by weight: 20-60 parts of ginseng, 80-120 parts of astragalus mongholicus, 20-60 parts of pericarpium papaveris, 10-15 parts of cuttle bone, 80-120 parts of red halloysite, 40-80 parts of longan seed, 60-100 parts of myrobalan, 40-80 parts of rhizoma corydalis, 70-130 parts of nutmeg, 20-30 parts of pericarpium arecae, 30-40 parts of fructus aurantii and 20-30 parts of semen platycladi. According to a preparation method, the active ingredients are extracted by regulating a PH (potential of hydrogen) value, and the extraction efficiency is improved. The composition can solve incidence reasons of the acute and chronic enteritis, the colitis and the bowel dysfunction basically by scientific compatibility of the raw materials, directly remove foci, achieves the purpose of radical cure, causes low burden to intestines and a stomach, and is safe, efficient, high in medicine utilization ratio and convenient to use.

Provided are a PEG-naloxone conjugate of general formula (II) and a pharmaceutical composition comprising the conjugate. In the conjugate, n is an integer in the range of 1-20. Also provided is a three-branched or four-branched conjugate of PEG and naloxone. Structural modification of naloxone with a hydrophilic polymer improves the pharmacokinetic properties of the drug, increase the water solubility of naloxone, improve the in vivo distribution of the drug, reduce the side effects of naloxone on central nervous system, and relieve bowel dysfunction and constipation caused by chronic administration of opioids. Also provided are a pharmaceutical composition comprising the conjugate of the invention and use of the conjugate.

The disclosure relates to a method of treating or preventing a condition in a subject associated with the activation of an opioid receptor in the periphery by administering an effective amount of 5-(2-methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide (Compound I). In particular, the disclosure relates to a method of treating or preventing opioid- induced constipation or opioid-induced bowel dysfunction in a human without reducing centrally-mediated opioid analgesia or producing central opioid withdrawal symptoms by administering an effective amount of Compound (I). The disclosure further relates to the use of Compound (I) for the preparation of a medicament for the treatment or prevention of a condition in a subject associated with the activation of an opioid receptor in the periphery.

The invention discloses a Chinese traditional medicine and western medicine compound preparation for treating constipation and a preparation method thereof. The preparation comprises a Chinese traditional medicine component, a western medicine component and auxiliaries. The Chinese traditional medicine component is prepared from the following raw medicinal materials: camellia seeds, Chinese torreya, common perilla fruits, semen raphani, semen biotae, dessert almonds, plum kernels, wild semen juglandis, peach kernels, walnut kernels, fructus cannabis, snakegourd seeds, fructus amomi and fructus alpiniae oxyphyllae. The western medicine component is functional oligosaccharide. Aiming at cold constipation caused by deficiency of yang, endogenous coldness, stagnation of intestines and stomach, non-transportation of yang qi and non-distribution of body fluid, the Chinese traditional medicine and western medicine compound preparation disclosed by the invention has the effects of warming the kidney and assisting yang, warming spleen and stomach, tonifying kidney and securing essence and treating stranguria and activating blood so as to achieve the purpose of loosening the bowel to relieve constipation. In addition, the functional oligosaccharide selected can be used for improving vitamin metabolism so as to prevent bowel dysfunction and inhibit growth of harmful bacteria and pathogenic bacteria in the intestinal tract, thereby exerting the effects of improving the environment of the intestinal tract and protecting the intestinal tract. By combining Chinese traditional medicines which treat root causes and western medicines which regulate, the preparation disclosed by the invention fully exerts a curative effect and constipation cured is not easy to replase.

This invention relates to treating gastrointestinal dysfunction with erythropoietin (EPO) or its analog.